Sustained terminal complement inhibition on the endothelium with ravulizumab in patients with atypical Haemolytic Uremic Syndrome
{{output}}
Introduction: Atypical haemolytic uremic syndrome (aHUS) is a rare and severe form of thrombotic microangiopathy caused by dysregulation of the alternative complement pathway, leading to sustained complement activation at endothe... ...
